OBJECTIVE: To evaluate the perfusate and systemic kinetics of oxaliplatin during hyperthermic intraperitoneal chemotherapy (HIPEC) using a selective analytical technique. METHODS: HIPEC was carried out in eight patients by the open abdomen coliseum technique for 30 min at 41.5-43 degrees C with an average of 427 mg/m(2) of oxaliplatin in 5% dextrose solution. Blood and perfusate samples were collected during the perfusion. Additional blood samples were taken up to 2 h after the end of perfusion. The analysis was performed by liquid chromatography and post-column derivatization with N,N-diethyldithiocarbamate using microwave heating. RESULTS: The mean elimination half-life of oxaliplatin in the perfusate was 29.5 min (range 21.1-41.2 min) and in the peripheral circulation 24.7 min (range 21.7-27.7 min). The ratio of the areas under the time concentration curve in perfusate and blood was 12.8 +/- 2.9. CONCLUSION: The systemic exposure of oxaliplatin measured after HIPEC using a selective analytical technique is considerably lower than previously reported results obtained by atomic absorption spectroscopy.
OBJECTIVE: To evaluate the perfusate and systemic kinetics of oxaliplatin during hyperthermic intraperitoneal chemotherapy (HIPEC) using a selective analytical technique. METHODS: HIPEC was carried out in eight patients by the open abdomen coliseum technique for 30 min at 41.5-43 degrees C with an average of 427 mg/m(2) of oxaliplatin in 5% dextrose solution. Blood and perfusate samples were collected during the perfusion. Additional blood samples were taken up to 2 h after the end of perfusion. The analysis was performed by liquid chromatography and post-column derivatization with N,N-diethyldithiocarbamate using microwave heating. RESULTS: The mean elimination half-life of oxaliplatin in the perfusate was 29.5 min (range 21.1-41.2 min) and in the peripheral circulation 24.7 min (range 21.7-27.7 min). The ratio of the areas under the time concentration curve in perfusate and blood was 12.8 +/- 2.9. CONCLUSION: The systemic exposure of oxaliplatin measured after HIPEC using a selective analytical technique is considerably lower than previously reported results obtained by atomic absorption spectroscopy.
Authors: P Pfeiffer; H Sørbye; H Ehrsson; T Fokstuen; J P Mortensen; L Baltesgard; K M Tveit; D Øgreid; H Starkhammar; I Wallin; C Qvortrup; B Glimelius Journal: Ann Oncol Date: 2005-11-15 Impact factor: 32.976
Authors: Loek A W de Jong; Fortuné M K Elekonawo; Philip R de Reuver; Andre J A Bremers; Johannes H W de Wilt; Frank G A Jansman; Rob Ter Heine; Nielka P van Erp Journal: Br J Clin Pharmacol Date: 2018-10-25 Impact factor: 4.335
Authors: Mila Bouchereau; Mai-Kim Gervais; Lucas Sideris; Marie-Hélène Loriot; Stéphane P Ahern; Pierre Dubé Journal: J Gastrointest Oncol Date: 2011-06
Authors: Belén Valenzuela; Ricardo Nalda-Molina; Pere Bretcha-Boix; Vanesa Escudero-Ortíz; Maria José Duart; Vicente Carbonell; Manuel Sureda; José Pascual Rebollo; Josep Farré; Antonio Brugarolas; Juan José Pérez-Ruixo Journal: AAPS J Date: 2011-01-06 Impact factor: 4.009
Authors: Gabriel Glockzin; Michael Gerken; Sven A Lang; Monika Klinkhammer-Schalke; Pompiliu Piso; Hans J Schlitt Journal: BMC Cancer Date: 2014-11-04 Impact factor: 4.430
Authors: Joshua C Leinwand; Gleneara E Bates; John D Allendorf; John A Chabot; Sharyn N Lewin; Robert N Taub Journal: Ann Surg Oncol Date: 2013-03-02 Impact factor: 5.344
Authors: Peter H Cashin; Haile Mahteme; Wilhelm Graf; Henning Karlsson; Rolf Larsson; Peter Nygren Journal: BMC Cancer Date: 2013-09-24 Impact factor: 4.430